The Tetrapeptide HAEE Promotes Amyloid-Beta Clearance from the Brain

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is marked by toxic amyloid-beta (Aβ) accumulation, causing synaptic dysfunction and neuroinflammation.
• The tetrapeptide HAEE shows promise by crossing the blood-brain barrier (BBB), inhibiting Aβ oligomer formation, and reducing amyloid burden.

Purpose of the Study:

• To elucidate the mechanisms behind HAEE's anti-amyloidogenic effects.
• To investigate HAEE-mediated Aβ clearance pathways both in vitro and in vivo.

Main Methods:

• ELISA to measure Aβ, IL-6, and TNFα levels in mouse brain tissue.
• Primary brain cell cultures and a BBB transwell model.
• Flow cytometry and microscopy to study cellular mechanisms.

Main Results:

• HAEE reduced brain Aβ levels by 35% and IL-6 by 40% in mice.
• HAEE facilitated Aβ transport across the BBB via LRP1 and P-glycoprotein (PgP).
• HAEE doubled microglial Aβ degradation rates and dissolved existing Aβ oligomers, while reducing microglial pro-inflammatory activation.

Conclusions:

• HAEE effectively reduces toxic Aβ oligomers and amyloid burden.
• HAEE mitigates neuroinflammation by decreasing IL-6 levels and microglial activation.
• HAEE presents a promising therapeutic strategy for Alzheimer's disease by targeting both Aβ pathology and neuroinflammation.